| Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway R Paumelle, D Tulashe, Z Kherrouche, S Plaza, C Leroy, S Reveneau, ... Oncogene 21 (15), 2309-2319, 2002 | 222 | 2002 |
| Concurrent fast and slow cycling of a transcriptional activator at an endogenous promoter TS Karpova, MJ Kim, C Spriet, K Nalley, TJ Stasevich, Z Kherrouche, ... Science 319 (5862), 466-469, 2008 | 155 | 2008 |
| Roles of stem cell factor/c-Kit and effects of Glivec®/STI571 in human uveal melanoma cell tumorigenesis G Lefevre, AL Glotin, A Calipel, F Mouriaux, T Tran, Z Kherrouche, ... Journal of Biological Chemistry 279 (30), 31769-31779, 2004 | 117 | 2004 |
| Exon 14 deleted MET receptor as a new biomarker and target in cancers AB Cortot, Z Kherrouche, C Descarpentries, M Wislez, S Baldacci, ... Journal of the National Cancer Institute 109 (5), djw262, 2017 | 98 | 2017 |
| Thirty years of research on met receptor to move a biomarker from bench to bedside A Furlan, Z Kherrouche, R Montagne, MC Copin, D Tulasne Cancer research 74 (23), 6737-6744, 2014 | 80 | 2014 |
| Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma RB Erlich, Z Kherrouche, D Rickwood, L Endo-Munoz, S Cameron, ... British journal of cancer 106 (1), 107-115, 2012 | 73 | 2012 |
| Trypanosoma cruzi: Tc52 released protein-induced increased expression of nitric oxide synthase and nitric oxide production by macrophages R Fernandez-Gomez, S Esteban, R Gomez-Corvera, K Zoulika, A Ouaissi The Journal of Immunology 160 (7), 3471-3479, 1998 | 68 | 1998 |
| Alterations in the PI3K pathway drive resistance to MET inhibitors in NSCLC harboring MET exon 14 skipping mutations P Jamme, M Fernandes, MC Copin, C Descarpentries, F Escande, ... Journal of Thoracic Oncology 15 (5), 741-751, 2020 | 59 | 2020 |
| Upstream CREs participate in the basal activity of minute virus of mice promoter P4 and in its stimulation in ras-transformed cells M Perros, L Deleu, JM Vanacker, Z Kherrouche, N Spruyt, S Faisst, ... Journal of virology 69 (9), 5506-5515, 1995 | 59 | 1995 |
| Shedding‐generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway F Ancot, C Leroy, G Muharram, J Lefebvre, J Vicogne, A Lemiere, ... Traffic 13 (9), 1261-1272, 2012 | 57 | 2012 |
| The multiple paths towards MET receptor addiction in cancer L Duplaquet, Z Kherrouche, S Baldacci, P Jamme, AB Cortot, MC Copin, ... Oncogene 37 (24), 3200-3215, 2018 | 48 | 2018 |
| Caspase-generated fragment of the Met receptor favors apoptosis via the intrinsic pathway independently of its tyrosine kinase activity J Lefebvre, G Muharram, C Leroy, Z Kherrouche, R Montagne, G Ichim, ... Cell death & disease 4 (10), e871-e871, 2013 | 48 | 2013 |
| Expression of the c-kit receptor in choroidal melanomas F Mouriaux, Z Kherrouche, CA Maurage, FX Demailly, P Labalette, ... Melanoma research 13 (2), 161-166, 2003 | 48 | 2003 |
| ASK-1 (apoptosis signal-regulating kinase 1) is a direct E2F target gene Z Kherrouche, A Blais, E Ferreira, Y De Launoit, D Monté Biochemical Journal 396 (3), 547-556, 2006 | 36 | 2006 |
| Optimization of routine testing for MET exon 14 splice site mutations in NSCLC patients C Descarpentries, F Leprêtre, F Escande, Z Kherrouche, M Figeac, ... Journal of Thoracic Oncology 13 (12), 1873-1883, 2018 | 35 | 2018 |
| PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells Z Kherrouche, D Monte, E Werkmeister, L Stoven, Y De Launoit, AB Cortot, ... Molecular oncology 9 (9), 1852-1867, 2015 | 30 | 2015 |
| Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors S Baldacci, J Mazieres, P Tomasini, N Girard, F Guisier, ... Oncotarget 8 (62), 105103, 2017 | 29 | 2017 |
| MET amplification increases the metastatic spread of EGFR-mutated NSCLC S Baldacci, Z Kherrouche, V Cockenpot, L Stoven, MC Copin, ... Lung Cancer 125, 57-67, 2018 | 27 | 2018 |
| Preparation and characterization of Zonyl-coated nanodiamonds with antifouling properties L Marcon, Z Kherrouche, J Lyskawa, D Fournier, D Tulasne, P Woisel, ... Chemical Communications 47 (18), 5178-5180, 2011 | 27 | 2011 |
| High MET overexpression does not predict the presence of MET exon 14 splice mutations in NSCLC: results from the IFCT PREDICT. amm study S Baldacci, M Figeac, M Antoine, C Descarpentries, Z Kherrouche, ... Journal of Thoracic Oncology 15 (1), 120-124, 2020 | 26 | 2020 |
David TulasneDirecteur de Recherche. INSERM在 ibl.cnrs.fr 的电子邮件经过验证
